Emily Fukuchi, MD; Barbara Fetterman, SCT (ASCP); Nancy Poitras, ACS, PMP; Walter Kinney, MD; Thomas Lorey, MD; Ramey D. Littell, MD To evaluate whether the presence of CIN 1 on ECC contributes to ...

Cervical intraepithelial neoplasia (CIN), also ... Treatment may not be necessary in cases of low-grade CIN 1 because the underlying infection often resolves on its own. For higher-grade disease ...

Here are 5 important questions to ask if you’ve been told you have cervical dysplasia: ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

“Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 ...

Another term for cervical dysplasia is cervical intraepithelial neoplasia, or CIN. The exact cause of cervical dysplasia is not known, however it has been linked to the human papillomavirus (HPV).

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.

The investigators assessed the efficacy of the vaccine against cervical intraepithelial neoplasia grade 2+ (CIN2+) lesions ... or a control vaccine at 0, 1 and 6 months; of these women, 92% ...

The Papanicolaou (Pap) smear is commonly used to screen for cervical cancer and ... Administration to screen for high-grade cervical intraepithelial neoplasia. Women with positive test results ...

The proportions of women with CIN 2+ and CIN 3+ on excisional procedure within 24 months of CIN 1 cervical biopsy were calculated with binomial exact CIs.